FDA’s Trade Name Pilot Should Include Third-Party Reviews, Industry Says
Executive Summary
Foreseeing battles over FDA and industry trade name discrepancies in a proposed pilot program, industry representatives are recommending that an independent, third-party review take place
You may also be interested in...
FDA Dangles Trade Name Review Pilot, But Industry Still Looking For The Bait
The success of FDA's pilot program for review of trade names will likely depend on the extent to which companies feel that taking on the burden will produce specific benefits for them
PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop
FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.